Fresenius Medical Care AG (NYSE:FMS) Receives Average Rating of “Hold” from Brokerages

Fresenius Medical Care AG (NYSE:FMS) has earned a consensus rating of “Hold” from the five analysts that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $24.30.

FMS has been the topic of a number of research reports. Truist Financial upped their target price on Fresenius Medical Care from $22.00 to $23.00 and gave the stock a “hold” rating in a research report on Monday, October 7th. Berenberg Bank started coverage on shares of Fresenius Medical Care in a research note on Wednesday. They set a “buy” rating and a $25.60 price target for the company. Finally, StockNews.com initiated coverage on shares of Fresenius Medical Care in a research note on Friday, November 1st. They issued a “strong-buy” rating on the stock.

Institutional Investors Weigh In On Fresenius Medical Care

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Allworth Financial LP grew its position in Fresenius Medical Care by 53.1% in the 3rd quarter. Allworth Financial LP now owns 1,675 shares of the company’s stock worth $36,000 after purchasing an additional 581 shares in the last quarter. Mercer Global Advisors Inc. ADV grew its holdings in shares of Fresenius Medical Care by 4.5% in the second quarter. Mercer Global Advisors Inc. ADV now owns 14,581 shares of the company’s stock valued at $278,000 after acquiring an additional 624 shares in the last quarter. Signaturefd LLC increased its position in shares of Fresenius Medical Care by 8.4% during the second quarter. Signaturefd LLC now owns 8,713 shares of the company’s stock valued at $166,000 after acquiring an additional 672 shares during the last quarter. Ritholtz Wealth Management lifted its holdings in Fresenius Medical Care by 2.5% during the second quarter. Ritholtz Wealth Management now owns 36,901 shares of the company’s stock worth $704,000 after acquiring an additional 895 shares during the period. Finally, Rhumbline Advisers boosted its position in Fresenius Medical Care by 6.7% in the second quarter. Rhumbline Advisers now owns 18,067 shares of the company’s stock worth $345,000 after purchasing an additional 1,128 shares during the last quarter. 8.25% of the stock is owned by hedge funds and other institutional investors.

Fresenius Medical Care Stock Up 1.3 %

FMS stock opened at $20.32 on Wednesday. The stock’s 50 day simple moving average is $20.35 and its 200 day simple moving average is $20.21. The company has a market cap of $11.92 billion, a P/E ratio of 20.95, a price-to-earnings-growth ratio of 0.96 and a beta of 0.91. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.09 and a current ratio of 1.46. Fresenius Medical Care has a fifty-two week low of $16.66 and a fifty-two week high of $22.76.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.